Former (Cara) President and Chief Executive Officer · Tvardi Therapeutics, Inc. (CARA)

Christopher Posner

A named executive officer of Tvardi Therapeutics in every fiscal year CompBrief holds from FY2023 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$2,570,260

Salary $203,933

FY2024: $1,065,879

2nd of 6 named executive officers at Tvardi Therapeutics by FY2025 total.

6 named officers on file for Tvardi Therapeutics, FY2025

Christopher Posner’s pay file — $29

  • 3 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Tvardi Therapeutics’s whole pay program stands against its peers

  • Tvardi Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CARA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 23, 2026 (DEF 14A).

Free

Get Christopher Posner’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Christopher Posner compensation by year

Tvardi Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Tvardi Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024FY2025
Salary$728,000$728,000$203,933
Bonus$0——
Stock awards$0——
Option awards$1,769,000$326,800—
Non-equity incentive$414,960——
Pension and deferred compensation$0——
All other$10,509$11,079$2,366,327
Total$2,922,469$1,065,879$2,570,260

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Tvardi Therapeutics, Inc. DEF 14A filed April 23, 2026, accession 0001104659-26-047695, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Tvardi Therapeutics, Inc. filed document, accession 0001104659-26-047695. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2026.

$2.9M
$1.1M
$2.6M
FY23
FY24
FY25
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
PSU181,000$134,483—
RSU71,000$52,753—
RSU26,000$19,318—
Option203,125—$10.06
Option283,000—$16.83
Option65,542—$10.46

Per the Outstanding Equity Awards at Fiscal Year-End table in Tvardi Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Tvardi Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Imran AlibhaiChief Executive Officer and Director$3,116,090
Christopher Posner · this pageFormer (Cara) President and Chief Executive Officer$2,570,260
John KauhChief Medical Officer$1,156,652
Dan ConnChief Financial Officer$1,139,451
Ryan MaynardFormer (Cara) Chief Financial Officer$1,131,912
Scott TerrillionFormer (Cara) General Counsel, Secretary and Chief Compliance Officer$1,112,438

The full Tvardi Therapeutics compensation record

free company brief

This page is one person within Tvardi Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Tvardi Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Christopher Posner's compensation dossier · One-time report. No refunds.